Skip to NavigationSkip to content

chloroquine's weekly COVID-19 news round-up

Image credit: CDC

Hydroxychloroquine dominates the latest coronavirus news this week. The anti-malaria drug, touted by President Trump as an effective COVID-19 treatment, has proved dangerous in a clinical trial in Brazil. Since Trump has praised the drug there has been an increase in misuse across the US. Critics have also alleged the President's continuous messaging about the treatment is motivated by his small financial link to Sanofi.

Fatal heart complications halt Brazilian study of chloroquine in treating COVID-19

Photo by Joegoauk Goa

A chloroquine study investigating its effects in treating the COVID-19 coronavirus in Brazil has been postponed for safety reasons.

It was discovered that taking a higher dose of the drug made some patients develop irregular heart rates that increased their risk of a fatal heart arrhythmia.

Trump again tells people to take Hydroxychloroquine to treat COVID-19, despite a lack of evidence

Photo by Gage Skidmore

President Trump continues to push the drug hydroxychloroquine as a potential coronavirus treatment despite a lack of evidence for its effectiveness.

In a recent press conference, the President said: “I’m not looking at it one way or another. But we want to get out of this. If it does work, it would be a shame if we didn’t do it early. What do I know? I’m not a doctor. But I have common sense. The FDA feels good about it, as you know, they approved it.”

EMA refuses to approve chloroquine for COVID-19 without sufficient data

Photo by Joegoauk Goa

The European Medicines Agency has restricted the general use of the drug chloroquine for coronavirus, but allowing its testing in clinical trials.

The drug has already been approved to treat malaria and autoimmune disease and these patients can still receive the treatment. However, people with COVID-19 must be on a trial to get the drug.

This is in contrast to the United States, with the FDA issuing an emergency authorization for chloroquine saying that research suggests it may have some benefits to people suffering from coronavirus.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches